|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
|
27878354 |
2017 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan.
|
27114605 |
2016 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
|
26812186 |
2016 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy of cetuximab alone or with irinotecan in patients with "quadruple wild type" or G13D-mutated metastatic colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based chemotherapy.
|
27246726 |
2016 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
|
22537608 |
2012 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC.
|
22441566 |
2012 |
|
rs112445441
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
|
rs121913529
|
|
|
0.030 |
GeneticVariation |
BEFREE |
To limit these variables, we previously studied a patient with metastatic colorectal cancer treated with polyclonal TILs targeting the <i>KRAS</i>(G12D) hotspot mutation, who experienced a partial response for 9 months.
|
31484655 |
2019 |
|
rs121913238
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using a system of paired NRAS-mutant and wild-type isogenic mCRC cell lines to explore signaling pathways engaged by the common oncogenic NRAS Q61K variant upon challenge with cetuximab, we uncovered an unexpected mechanism of resistance to cetuximab involving dysregulation of the ephrin-A1/EphA2 signaling axis.
|
28560458 |
2017 |
|
rs121913238
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using isogenic mCRC cells with a heterozygous knock-in of the NRAS activating mutation Q61K, we aimed to elucidate the mechanism(s) by which mutant NRAS blocks cetuximab from inhibiting mCRC growth.
|
27636997 |
2016 |
|
rs121913529
|
|
|
0.030 |
GeneticVariation |
BEFREE |
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
|
26662311 |
2016 |
|
rs121913529
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer.
|
27959684 |
2016 |
|
rs121913238
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We report two cases of mCRC with a Q61K NRAS mutation that had a favorable response to bevacizumab and the histone deacetylase inhibitor valproic acid.
|
23400451 |
2013 |
|
rs61764370
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site (LCS6) within the 3'untranslated region (3'UTR) of KRAS (rs61764370) and clinical outcome in metastatic colorectal cancer (mCRC) patients receiving cetuximab.
|
23167843 |
2012 |